CN103127190A - Preparation method of domestic Brazilian ginseng extract, and application thereof in aspects of medicine and health care - Google Patents
Preparation method of domestic Brazilian ginseng extract, and application thereof in aspects of medicine and health care Download PDFInfo
- Publication number
- CN103127190A CN103127190A CN2013100705493A CN201310070549A CN103127190A CN 103127190 A CN103127190 A CN 103127190A CN 2013100705493 A CN2013100705493 A CN 2013100705493A CN 201310070549 A CN201310070549 A CN 201310070549A CN 103127190 A CN103127190 A CN 103127190A
- Authority
- CN
- China
- Prior art keywords
- pfaffia
- extract
- domestic
- preparation
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 235000020710 ginseng extract Nutrition 0.000 title abstract 4
- 241000241627 Pfaffia Species 0.000 claims abstract description 56
- 239000000284 extract Substances 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000002552 dosage form Substances 0.000 claims abstract description 17
- 241000208340 Araliaceae Species 0.000 claims abstract description 9
- 230000002929 anti-fatigue Effects 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 235000008434 ginseng Nutrition 0.000 claims abstract description 8
- 241000759815 Hebanthe paniculata Species 0.000 claims abstract description 7
- 239000004615 ingredient Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 229940023488 pill Drugs 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 239000006196 drop Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 241000219317 Amaranthaceae Species 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 5
- -1 abundant suspendible Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 239000007941 film coated tablet Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 239000006189 buccal tablet Substances 0.000 claims description 4
- 229940046011 buccal tablet Drugs 0.000 claims description 4
- 239000008298 dragée Substances 0.000 claims description 4
- 239000007938 effervescent tablet Substances 0.000 claims description 4
- 239000002662 enteric coated tablet Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 235000015091 medicinal tea Nutrition 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000007940 sugar coated tablet Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000000874 microwave-assisted extraction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 16
- 230000003203 everyday effect Effects 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 210000001541 thymus gland Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 5
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 5
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 5
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229940100243 oleanolic acid Drugs 0.000 description 5
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 235000019082 Osmanthus Nutrition 0.000 description 3
- 241000333181 Osmanthus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940108605 cyclophosphamide injection Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027906 Monocytosis Diseases 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of a domestic Brazilian ginseng extract, and an application thereof in the aspects of medicine and health care, belongs to the technical field of medicine, and discloses extract of amaranthaceae pfaffia Brazilian plant ginseng Pfaffia paniculata ('domestic Brazilian ginseng' in short) planted in the People's Republic of China, and a preparation method thereof. The domestic Brazilian ginseng extract is characterized by containing effective ingredients for treating malignant tumor, and enhancing body anti-fatigue action. Auxiliary materials which are permitted to add by national and industry standards, and laws and regulations can be added to the domestic Brazilian ginseng extract prepared by the preparation method; any dosage form of drug and related healthy product are prepared by a proper method; the drug can be applied to the treatment of the malignant tumor; and the related healthy product can be used for enhancing the anti-fatigue ability of a human body.
Description
Technical field
Amaranthaceae (Amaranthaceae) Fa Feier that the present invention relates to the domestic introducing and planting of a kind of People's Republic of China (PRC) belongs to (Pfaffia) plant pfaffia Pfaffia paniculata and (claims again ' Fa Feier ginseng ', ' South America Herba Amaranthi tricoloris ' etc., under referred to as ' domestic pfaffia ') extract and preparation method thereof, it is characterized in that this extract contains the effective ingredient for the treatment of malignant tumor, enhancing body antifatigue effect.
Background technology
Amaranthaceae Amaranthaceae genus Pfaffia Pfaffia Pedersen plant is human-like shrub or the undershrub of overgrowing, and the whole world is total to approximately 90 kinds, makes medicinal 5 kinds that have, and is called again pfaffia because having the tonic effect similar with the Araliaceae Radix Ginseng.Mainly be distributed in the Tropical rain forests such as Brazil, Ecuador, Panama regional, the most representative plant is Pfaffia paniculata.This platymiscium had the botany record in 1826 first, and main medicinal part is root, and the effects such as tonifying YANG, calmness, antitumor, treatment ulcer, rheumatic arthritis and blood sugar lowering are arranged, and used history in existing more than 300 year, was local a kind of important herbal medicine among the people.be used as tonic and immunostimulant in American-European draft medical science, be widely used in the balance hormonal system, strengthen immune system, reduce the family planning side effects of pharmaceutical drugs, reduce cholesterol, neutralize a toxin and nourish tonic as whole body, and be used for the treatment of by the remorse disease of Epstein-Barr and chronic fatigue syndrome cause fatigue, hypoglycemia, sexual impotence, arthritis, anemia, diabetes, cancer, monocytosis, hypertension, premenstrual syndrome, climacteric and hormone disorder etc., pfaffia and steroid are united use in addition can increase myogenesis and endurance and be free from side effects.
From calendar year 2001; one of inventor herein doctor Ma Xiaojun introduces Pfaffia paniculata respectively in Guangxi, gradually artificial culture is carried out in river, Sichuan from Brazil; obtained success; and realized implantation in large scale production in present patent application unit, and prove that by preliminary chemistry and pharmacodynamics work domestic Pfaffia paniculata and place of production pfaffia are basic identical.
The present invention proposes on the basis of above-mentioned domestic pfaffia being carried out preliminary Chemical Decomposition and pharmacodynamic study.Disclosure of the invention a kind of preparation method of domestic pfaffia Pfaffia paniculata extract of introducing a fine variety.This preparation method simple and feasible, be very beneficial for suitability for industrialized production, by the animal pharmacodynamic experiment, prove that the extract that this preparation method is produced contains the effective ingredient for the treatment of malignant tumor, improving human body immune function, enhancing body antifatigue effect, can be used for the treatment of malignant tumor, also can be used for preparing the healthy Related product of various enhancing human body anti-fatigue abilities.
Summary of the invention
The present invention adopts the solvent extraction separation method to prepare domestic pfaffia extract.concrete steps are as follows: after domestic pfaffia medical material is suitably pulverized, with 70% to 100% moisture lower alcohols (methanol, ethanol), in static state or dynamically, room temperature or heating (comprise dipping, percolation, reflux, microwave etc.) extract, the extraction solvent load is 5～15 times of medical material, extraction time is 1～3 time, extracting liquid filtering, decompression or air-distillation are reclaimed alcoholic solvent to collecting liquid alcohol content lower than after 10%, continue evaporation and concentration to distinguish the flavor of without alcohol (1.05～1.25/80 ℃ of relative densities), add 0.2～5 times of amount of water, abundant suspendible, suspension fully extracts with petroleum ether, check reactionless with vanillin-sulfuric acid ethanol reagent after concentrated to extract, using ethyl acetate instead fully extracts, check reactionless with vanillin-sulfuric acid ethanol reagent after concentrated to extract, using butanols instead fully extracts again, check reactionless with vanillin-sulfuric acid ethanol reagent after concentrated to extract, remove organic solvent, it is 1.1～1.50/80 ℃ that lower layer of water suspension decompression or atmospheric evaporation are concentrated to relative density, it is dry that (drying mode can be: oven dry, decompression drying, spray drying etc.) be equal to or less than 3.0% to moisture, pulverize, sieve, both.
The extract that the present invention makes is being produced medicine, during healthy related preparations product, can add country and industry standard and rules to allow the adjuvant that adds, such as: water, starch, sucrose, dextrin, mannitol, glycerol, silicon derivative, magnesium stearate, Pulvis Talci etc.
The pfaffia extract that the present invention makes can add country and industry standard and rules to allow the adjuvant that adds, make any dosage form of medicine by proper method, these dosage forms are as tablet, sugar coated tablet, film coated tablet, enteric coated tablet, buccal tablet, effervescent tablet, hard capsule, soft capsule, pill, drop pill, granule, medicinal tea, powder, unguentum, sublimed preparation, suspensoid, solution, injection, Liposomal formulation, suppository, plaster, ointment, cream, spray, drop, patch etc.The preferential dosage form of selecting of the present invention is oral formulations, as tablet, capsule, granule, mixture etc.The pfaffia extract medicine of above-mentioned dosage form can be used the treatment of fourth malignant tumor (hepatocarcinoma, gastric cancer, pulmonary carcinoma, breast carcinoma, etc.).
The pfaffia extract that the present invention makes also can add country and industry standard and rules to allow the adjuvant that adds, make any dosage form of health promoting product (as: health food, functional food, functional drinks etc.) by proper method, these dosage forms are as tablet, sugar coated tablet, film coated tablet, enteric coated tablet, buccal tablet, effervescent tablet, hard capsule, soft capsule, pill, drop pill, granule, medicinal tea, powder, unguentum, sublimed preparation, suspensoid, solution.The preferential dosage form of selecting of the present invention is oral formulations, as tablet, capsule, granule, mixture etc.The pfaffia health promoting product of above-mentioned dosage form can be applicable to strengthen the anti-fatigue ability of people's body.
Description of drawings
Fig. 1 is pfaffia extract thin layer chromatogram chromatography condition: toluene: ethyl acetate: glacial acetic acid=6: 4: 0.4
Developer: 10% sulphuric acid-ethanol
Fig. 2 is oleanolic acid reference substance test HPLC collection of illustrative plates
Fig. 3 is the parallel HPLC collection of illustrative plates of testing for the first time of pfaffia extract sample
Fig. 4 is the parallel HPLC collection of illustrative plates of testing for the second time of pfaffia extract sample
domestic pfaffia medicinal material coarse powder with 85% alcohol reflux 2 times, adds 10 times of amounts of ethanol, reflux, extract, 2 hours first, add 6 times of amounts of ethanol for 2 times, reflux, extract, 1 hour, extracting liquid filtering, decompression is received alcoholic solvent to collecting liquid alcohol content lower than after 10%, continue evaporation and concentration to distinguish the flavor of without alcohol (1.15/80 ℃ of relative density), add 1 times of amount of water, abundant suspendible, it is concentrated rear reactionless with the inspection of vanillin-sulfuric acid ethanol reagent that suspension fully is extracted to extract with petroleum ether, using ethyl acetate instead fully is extracted to extract and checks reactionless with vanillin-sulfuric acid ethanol reagent after concentrated, using n-butyl alcohol instead fully is extracted to extract and checks reactionless with vanillin-sulfuric acid ethanol reagent after concentrated again, remove organic solvent, it is 1.35/80 ℃ that lower layer of water suspension reduction vaporization is concentrated to relative density, decompression drying arrives moisture lower than 3.0%, pulverize and sieve and both got.
The pfaffia extract of example 1 preparation has obvious saponin reaction.
After the pfaffia extract 5.0g precise weighing of example 1 preparation, with 2% sulphuric acid back hydrolysis 2 hours, the filtering acid solution was washed to neutrality, oven dry, with methanol extraction 3 times, each methanol 50ml refluxed 50 minutes, the extracting liquid filtering evaporate to dryness, residue, washes in the 100ml measuring bottle more than 3 times with methanol wash, adds methanol and gets sample liquid to scale.Make 1.0mg/ml concentration reference substance solution with dissolve with methanol oleanolic acid reference substance.Get each 5 μ l of above two solution, take toluene-ethyl acetate-glacial acetic acid (6: 5: 0.5) as developing solvent, launch on silica gel g thin-layer plate, after solvent is flung in expansion, with 10% sulphuric acid-ethanol reagent spray, 105 ℃ of colour developings, the aobvious speckle (see Figure of description) consistent with the oleanolic acid color and luster on the reference substance relevant position.
Get each 10 μ l of above-mentioned different liquid, the alkyl linked silica gel reversed phase chromatography of C-18 post is carried out the high performance liquid chromatography chromatography, chromatographic condition is: imitate theoretical cam curve greater than 10,000 with respect to the post of oleanolic acid, mobile phase is: methanol-water-phosphoric acid (88-12-0.6), UV-detector detects wavelength: 220nm, column temperature: 25 ℃, flow velocity 1.0ml/min.Result detects oleanolic acid (seeing Figure of description), and content is greater than 7.0%.
The extract that the present invention makes proves its beneficial effect by following pharmacodynamic experiment:
One, antitumor action
(1) anti-S
180The solid tumor experiment
1. experiment material
1.1 medicine: the pfaffia extract, with example 1 method preparation, before experiment, water is made into desired concn; Positive control drug: cyclophosphamide Injection: Shanxi Powerdone Pharmaceutical Co., Ltd. produces, lot number 04110603, and specification: the 200mg/ bottle, make with 1%CMC-Na water the solution that concentration is 1mg/ml.
1.2 laboratory animal: cleaning level KM mice, body weight 18～22g, male and female half and half, studying medicine Experimental Animal Center by Guangxi medical courses in general people provides, certificate number: SCXK osmanthus 2009-0002.。
1.3 instrument: EL204 ten thousand/gram electronic balance (Mettler-Toledo Instrument (Shanghai) Co., Ltd.), 37XB inverted microscope (Shanghai optical instrument six factories).
2. experimental technique
2.1 modeling method
Choose the S of the obvious bulge of abdominal part of raising 7 days
180The transplanted tumor mice, the skin of abdomen sterilization is extracted ascites with disposable sterilized injector, puts into aseptic beaker, cell counting, normal saline dilution cell concentration to 1 * 10
7/ mL, the cancerous cell suspension 0.2mL of every mice left side oxter subcutaneous vaccination normal saline dilution.
2.2 group technology
To connect the tumor mice and be divided at random model group next day, cyclophosphamide group, pfaffia extract group, 12 every group.
2.3 medication
Set time every day section, administration concrete grammar and measure as follows:
Model group: every day, gavage gave normal saline, 0.2mL/10g, 10d continuously
Cyclophosphamide group: inject cyclophosphamide solution every day, 20mg/kg, 10d continuously
Pfaffia extract group:
Every day, gavage gave pfaffia extract dry powder suspension, 0.2mL/10g (being equivalent to raw medicinal herbs 8g/kg), 10d
2.4 record and method of drawing material
Record activity situation and the body weight of mice, animal lotus tumor the 16th day is put to death mice and is got thymus, spleen, peels off the tumor body, and thymus, spleen, tumor body are weighed.Tumor control rate (%)=[1-(average test group tumor weight/average control group tumor is heavy)] * 100%.Thymus index=thymus average weight (mg)/average weight (g); Index and spleen index=spleen average weight (mg)/average weight (g).Data are used
Expression, group difference is checked with t.The results are shown in Table 1, table 2.
Table 1 is respectively organized mouse tumor and is heavily reached tumor control rate relatively
Compare * * P＜0.01, * P＜0.05 with model group
Find out from table: compare with model group, pfaffia extract group obviously suppresses the growth (p＜0.05) of tumor.
Table 2 is respectively organized mice organs index relatively (mg/g body weight)
Compare * * P＜0.01, * P＜0.05 with model group
Find out from table: compare with model group, the cyclophosphamide group has all obviously reduced spleen index and the thymus index (p＜0.05) of tested mice, illustrates that cyclophosphamide has obvious immunosuppressive action.The organ index of pfaffia extract group does not relatively have significant difference than model group, illustrates that the pfaffia extract does not have inhibitory action to the immune function of mice.
(2) anti-H
22Tumor experiment
1. experiment material
1.1 medicine: the pfaffia extract, with example 1 method preparation, before experiment, water is made into desired concn; Positive control drug: cyclophosphamide Injection: Shanxi Powerdone Pharmaceutical Co., Ltd. produces, lot number 04110603, and specification: the 200mg/ bottle, make with 1%CMC-Na water the solution that concentration is 1mg/ml.
1.2 laboratory animal: cleaning level KM mice, body weight 18～22g, male and female half and half are provided certificate number by Guangxi Medical University's medical experiment animal center: SCXK osmanthus 2009-0002.。
1.3 instrument: EL204 ten thousand/gram electronic balance (Mettler-Toledo Instrument (Shanghai) Co., Ltd.), 37XB inverted microscope (Shanghai optical instrument six factories).
2. experimental technique
2.1 modeling method
Choose the H of the obvious bulge of abdominal part of raising 7 days
22The transplanted tumor mice, the skin of abdomen sterilization is extracted ascites with disposable sterilized injector, puts into aseptic beaker, cell counting, normal saline dilution cell concentration to 1 * 10
7/ mL, the cancerous cell suspension 0.2mL of every mouse peritoneal inoculation normal saline dilution.
2.2 group technology
To connect the tumor mice and be divided at random model group next day, cyclophosphamide group, pfaffia extract group, 12 every group.
2.3 medication
Set time every day section, administration concrete grammar and measure as follows:
Model group: every day, gavage gave normal saline, 0.2mL/10g, 10d continuously
Cyclophosphamide group: inject cyclophosphamide solution every day, 20mg/kg, 10d continuously
Pfaffia extract group:
Every day, gavage gave pfaffia extract dry powder suspension, 0.2mL/10g (being equivalent to raw medicinal herbs 8g/kg), 10d
2.4 record and method of drawing material
Record activity situation and the body weight of mice, animal lotus tumor the 16th day is put to death mice and is got thymus, spleen, peels off the tumor body, and thymus, spleen, tumor body are weighed.Tumor control rate (%)=[1-(average test group tumor weight/average control group tumor is heavy)] * 100%.Thymus index=thymus average weight (mg)/average weight (g); Index and spleen index=spleen average weight (mg)/average weight (g).Data are used
Expression, group difference is checked with t.The results are shown in Table 3, table 4.
Table 3 is respectively organized mouse tumor and is heavily reached tumor control rate relatively
Compare * * P＜0.01, * P＜0.05 with model group
Find out from table: compare with model group, No. 3 groups of pfaffia obviously suppress the growth (p＜0.05) of tumors.
Table 4 is respectively organized mice organs index relatively (mg/g body weight)
Compare * * P＜0.01, * P＜0.05 with model group
Find out from table: compare with model group, the cyclophosphamide group has all obviously reduced spleen index and the thymus index (p＜0.05) of tested mice, illustrates that cyclophosphamide has obvious immunosuppressive action.The organ index of pfaffia extract group does not relatively have significant difference than model group, illustrates that the pfaffia extract does not have inhibitory action to the immune function of mice.
Two, antifatigue effect (power exhausts swimming test)
1. experiment material
1.1 medicine: the pfaffia extract, with example 1 method preparation, before experiment, water is made into desired concn; The contrast medicine: Radix Ginseng: purchase in Nanning source of students prepared slices of Chinese crude drugs Co., Ltd (prepared slices of Chinese crude drugs GMP enterprise), lot number 20120224 is ground into fine powder, makes suspension during experiment.
1.2 laboratory animal: cleaning level KM mice, body weight 18～22g, male and female half and half are provided certificate number by Guangxi Medical University's medical experiment animal center: SCXK osmanthus 2009-0002.
1.3 instrument: electronic stopclock, model: Shanghai diamond DM1-001.
2. experimental technique
2.1 group technology
The mice that adapts to 3 days is divided into the Radix Ginseng group at random, pfaffia extract group, and get with batch normal blank group of 12 conducts of normal health mice.
2.2 medication
Set time every day section, administration concrete grammar and measure as follows:
Normal blank group: every day, gavage gave normal saline, 0.2mL/10g, 15d continuously
The Radix Ginseng group: every day, gavage gave the Radix Ginseng powder suspension, 5g crude drug/kg, 15d continuously
Pfaffia extract group:
Every day, gavage gave pfaffia extract dry powder suspension, 0.2mL/10g (being equivalent to raw medicinal herbs 8g/kg), 15d
2.3 record and method of drawing material
The specification of swimming pool is 185cm * 73cm * 50cm, depth of water 30cm during swimming, 0.5 ℃ of water temperature 25 scholar inserts swimming pool with mouse tail root load 10% body weight silk, records the time of mice from entry swimming to drained (head submerged can not emerge in 10 seconds exhaust standard for power).See Table 5.
Table 5 is respectively organized mouse swimming test relatively
Compare * * P＜0.01, * P＜0.05 with the blank group
Find out from table: compare with the blank group, but the time (P＜0.05) of pfaffia extract significant prolongation mice burden swimming
Capsule
[prescription] prepares pfaffia extract powder 200g medical starch 200g magnesium stearate 3g with example 1 method
Make altogether 1000 of hard capsules.
[method for making] with pfaffia extract powder, and packing into by equivalent increment method and medical starch, the abundant mix homogeneously of magnesium stearate gets final product in hard capsule case.
Tablet
[prescription] pfaffia extract powder 200g medical starch 200g magnesium stearate 2g
Make altogether 1000 Film coated tablets.
[method for making] fully mixes pfaffia extract powder all by equivalent increment method and medical starch, magnesium stearate, and with 60% ethanol superzapping sheet granule, dry, granulate add the abundant mix homogeneously of magnesium stearate, and tabletting, film coating get final product.
Granule
[prescription] pfaffia extract powder 200g dextrin 780g sweeting agent and other adjuvant 20g
Make altogether 100 bags.
[method for making] with pfaffia extract powder, and by the abundant mix homogeneously of equivalent increment method and dextrin, sweeting agent etc., with 60% ethanol granule processed, drying, granulate are sub-packed in appropriate containers and get final product.
Claims (3)
1. the Amaranthaceae of the domestic introducing and planting of the People's Republic of China (PRC) (Amaranthaceae) Fa Feier belongs to (Pfaffia) plant pfaffia Pfaffia paniculata and (claims again ' Fa Feier ginseng ', ' South America Herba Amaranthi tricoloris ' etc., under referred to as ' domestic pfaffia ') extract and preparation method thereof, it is characterized in that this extract contains the treatment malignant tumor, strengthens the effective ingredient of human body antifatigue effect.
2. the preparation technology of domestic pfaffia extract claimed in claim 1 is as follows:
2.1 domestic pfaffia medicinal material coarse powder adopts high concentration lower alcohols (methanol, ethanol) to extract;
After 2.2 extracting solution reclaims alcohols solvent, residual solution adds 0.2 to 5 times of volume that water is equivalent to residual solution, abundant suspendible, suspension fully extracts with organic solvents such as petroleum ether, ethyl acetate, butanols respectively, separate and remove the organic solvent part, the water layer solution evaporation is condensed into the thick paste shape, and drying both got;
2.3 the explanation of relevant said extracted technique:
1) concentration of 2.1 described lower alcohols is 70% to 100%;
2) 2.1 described extracting method can be: the several different methods such as backflow, dipping, percolation, ultrasonic, microwave extraction;
3) 2.2 described water layer solution evaporations are condensed into the thick paste concentration of thick paste shape and are: 1.1～1.50/80 ℃ of relative densities;
4) 2.2 described drying meanss are the modes such as room temperature oven dry, decompression drying, spray drying, dry rear moisture≤3.0%.
3. the application of the domestic pfaffia extract of claim 1 preparation aspect medicine, health care:
3.1 the domestic pfaffia extract of claim 1 preparation can add country and industry standard and rules to allow the adjuvant that adds, make any dosage form of medicine by proper method, these dosage forms are as tablet, sugar coated tablet, film coated tablet, enteric coated tablet, buccal tablet, effervescent tablet, hard capsule, soft capsule, pill, drop pill, granule, medicinal tea, powder, unguentum, sublimed preparation, suspensoid, solution, injection, Liposomal formulation, suppository, plaster, ointment, cream, spray, drop, patch etc.The preferential dosage form of selecting of the present invention is oral formulations, as tablet, capsule, granule, mixture etc.The pfaffia extract medicine of above-mentioned dosage form can be used for the treatment of malignant tumor (hepatocarcinoma, gastric cancer, pulmonary carcinoma, breast carcinoma, etc.);
3.2 the domestic pfaffia extract of claim 1 preparation also can add country and industry standard and rules to allow the adjuvant that adds, make any dosage form of health promoting product (as: health food, functional food, functional drinks etc.) by proper method, these dosage forms are as tablet, sugar coated tablet, film coated tablet, enteric coated tablet, buccal tablet, effervescent tablet, hard capsule, soft capsule, pill, drop pill, granule, medicinal tea, powder, blue or green agent, sublimed preparation, suspensoid, solution.The preferential dosage form of selecting of the present invention is oral formulations, as tablet, capsule, granule, mixture etc.The pfaffia health promoting product of above-mentioned dosage form can be applicable to strengthen the anti-fatigue ability of people's body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100705493A CN103127190A (en) | 2013-03-06 | 2013-03-06 | Preparation method of domestic Brazilian ginseng extract, and application thereof in aspects of medicine and health care |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100705493A CN103127190A (en) | 2013-03-06 | 2013-03-06 | Preparation method of domestic Brazilian ginseng extract, and application thereof in aspects of medicine and health care |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103127190A true CN103127190A (en) | 2013-06-05 |
Family
ID=48488061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100705493A Withdrawn CN103127190A (en) | 2013-03-06 | 2013-03-06 | Preparation method of domestic Brazilian ginseng extract, and application thereof in aspects of medicine and health care |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127190A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103719992A (en) * | 2013-12-25 | 2014-04-16 | 吉林农业大学 | A kind of direct drink type ginseng acetic acid beverage and production method thereof |
| CN104013656A (en) * | 2014-06-20 | 2014-09-03 | 广西壮族自治区药用植物园 | Preparation method of domestic pfaffia glomerate ethyl acetate extract and use thereof in medicine |
| CN105852130A (en) * | 2016-05-24 | 2016-08-17 | 朱启标 | Preparation method of ginseng health care product and product of preparation method |
| CN109010475A (en) * | 2018-08-30 | 2018-12-18 | 宁波珐菲亚食品股份有限公司 | A kind of Ms's washing lotion |
| CN109820980A (en) * | 2019-04-13 | 2019-05-31 | 浙江农林大学 | A kind of traditional Chinese medicine composition for relieving dysmenorrhea based on Brazilian ginseng, healthy food and preparation method thereof |
| CN112042942A (en) * | 2020-09-02 | 2020-12-08 | 江西中医药大学 | A Chinese medicinal food containing Pfaffia paniculata (L.) kuntze and its preparation method |
| CN112772764A (en) * | 2021-01-18 | 2021-05-11 | 江西中医药大学 | Health-care chewing gum and preparation method thereof |
-
2013
- 2013-03-06 CN CN2013100705493A patent/CN103127190A/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103719992A (en) * | 2013-12-25 | 2014-04-16 | 吉林农业大学 | A kind of direct drink type ginseng acetic acid beverage and production method thereof |
| CN103719992B (en) * | 2013-12-25 | 2015-08-26 | 吉林农业大学 | A kind of straight drink type ginseng vinegar acid beverage and production method thereof |
| CN104013656A (en) * | 2014-06-20 | 2014-09-03 | 广西壮族自治区药用植物园 | Preparation method of domestic pfaffia glomerate ethyl acetate extract and use thereof in medicine |
| CN105852130A (en) * | 2016-05-24 | 2016-08-17 | 朱启标 | Preparation method of ginseng health care product and product of preparation method |
| CN109010475A (en) * | 2018-08-30 | 2018-12-18 | 宁波珐菲亚食品股份有限公司 | A kind of Ms's washing lotion |
| CN109820980A (en) * | 2019-04-13 | 2019-05-31 | 浙江农林大学 | A kind of traditional Chinese medicine composition for relieving dysmenorrhea based on Brazilian ginseng, healthy food and preparation method thereof |
| CN112042942A (en) * | 2020-09-02 | 2020-12-08 | 江西中医药大学 | A Chinese medicinal food containing Pfaffia paniculata (L.) kuntze and its preparation method |
| CN112772764A (en) * | 2021-01-18 | 2021-05-11 | 江西中医药大学 | Health-care chewing gum and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singhuber et al. | Aconitum in traditional Chinese medicine—a valuable drug or an unpredictable risk? | |
| CN103127190A (en) | Preparation method of domestic Brazilian ginseng extract, and application thereof in aspects of medicine and health care | |
| CN105079061A (en) | Pseudo-ginseng active medicine prepared by adopting ultramicro wall-breaking grinding technology as well as health product and preparation method thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN102617698B (en) | Method for preparing fine dioscin and application of fine dioscin | |
| Li | Chinese herbal medicine | |
| WO2021142920A1 (en) | Traditional chinese medicine composition for treating lung cancer, and preparation and use thereof | |
| CN101352468A (en) | New application of horned melon and its extract in the preparation of antitumor drugs | |
| CN1985864B (en) | Medicine composition prepared mainly from glycyrrhizic acid or its salt, ginseng and glossy ganoderma | |
| CN101011543B (en) | A new antitumor drug composition | |
| CN109248188A (en) | A kind of preparation method and applications of goldspink root extract | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN107893035A (en) | A kind of culture medium of Hericium erinaceus, sealwort bioconversion mycelium, the mycelial extract of sealwort bioconversion and application thereof | |
| CN104435293B (en) | Application of ethanolic extract of total triterpenes of Schisandra chinensis in the preparation of anti-arthritis drugs | |
| CN101612181A (en) | Novel application of cerbera manghas and crude extract thereof in preparation of antitumor drugs | |
| CN101664423A (en) | Hypoglycemic active part of osmanthus fragrans, preparation method and application thereof | |
| CN1961898B (en) | An antitumor compound pharmaceutical composition with barbed stullcap and preparation process thereof | |
| CN1775267A (en) | A kind of open arrow extract and its preparation method and application | |
| CN1954838B (en) | Medical composite of antineoplastic | |
| CN109771454A (en) | Use of Chaga Mushroom Extract in the preparation of preparations for treating and/or preventing liver damage-related diseases caused by high-fat diet | |
| CN103830426B (en) | One treats vasculitic Chinese medicine composition | |
| CN1994426B (en) | Preparation method, and identification and assaying method of 'Sheng Mai' soft capsule | |
| CN1961895B (en) | A novel anticancer pharmaceutical composition and preparation method thereof | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20130605 |